Karyopharm Therapeutics Inc (KPTI) concluded trading on Thursday at a closing price of $0.99, with 8.36 million shares of worth about $8.28 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.35% during that period and on October 31, 2024 the price saw a gain of about 17.81%. Currently the company’s common shares owned by public are about 114.92M shares, out of which, 114.06M shares are available for trading.
Stock saw a price change of 21.30% in past 5 days and over the past one month there was a price change of 11.98%. Year-to-date (YTD), KPTI shares are showing a performance of 14.43% which increased to 13.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.62 but also hit the highest price of $1.95 during that period. The average intraday trading volume for Karyopharm Therapeutics Inc shares is 601.89K. The stock is currently trading 15.12% above its 20-day simple moving average (SMA20), while that difference is up 23.67% for SMA50 and it goes to -3.24% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Karyopharm Therapeutics Inc (NASDAQ: KPTI) currently have 114.92M outstanding shares and institutions hold larger chunk of about 55.08% of that.
The stock has a current market capitalization of $123.41M and its 3Y-monthly beta is at 0.18. It has posted earnings per share of -$1.19 in the same period. It has Quick Ratio of 3.56. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KPTI, volatility over the week remained 10.59% while standing at 6.78% over the month.
Stock’s fiscal year EPS is expected to rise by 40.62% while it is estimated to increase by 8.91% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on January 19, 2023 offering an Overweight rating for the stock and assigned a target price of $8 to it. Coverage by RBC Capital Mkts stated Karyopharm Therapeutics Inc (KPTI) stock as an Outperform in their note to investors on November 04, 2022, suggesting a price target of $10 for the stock. On February 09, 2022, JP Morgan Upgrade their recommendations, while on November 19, 2021, Morgan Stanley Resumed their ratings for the stock with a price target of $10. Stock get a Mkt perform rating from SVB Leerink on August 06, 2021.
